<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02126098</url>
  </required_header>
  <id_info>
    <org_study_id>PUMCH-PULMONARY DISEASES</org_study_id>
    <secondary_id>2011BA11B17</secondary_id>
    <nct_id>NCT02126098</nct_id>
  </id_info>
  <brief_title>Observation Study of Clinical Manifestation and Outcome in Chinese Patients With Pulmonary Vasculitis</brief_title>
  <official_title>Cohort Study of Chinese Patients With Pulmonary Vasculitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to observe the clinical manifestation, Lab findings including&#xD;
      chest CT scans, pathological findings and outcomes in chinese patients with pulminary&#xD;
      vasculitis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Presentation of patient with suspected vasculitis&#xD;
&#xD;
        1. Established diagnosis Clinical findings Laboratory workup Tissue biopsy Angiogram where&#xD;
           appropriate&#xD;
&#xD;
        2. Evaluating respiratory system Chest HRCT Pulmonary function test Bronchoscopy exam(BALF,&#xD;
           TBB) Lung biopsy(needle biopsy, VAST)&#xD;
&#xD;
        3. screening underlying damage to other system Paranasal sinus, vision &amp; audition Nervous&#xD;
           system Kidney Gastrointestinal tract Heart &amp; vessel Skin Hematology Muscle, bone &amp; joint&#xD;
&#xD;
        4. Treatment&#xD;
&#xD;
        5. Prognosis&#xD;
&#xD;
      Evaluation&#xD;
&#xD;
        1. Study visits occurred at baseline; at weeks 4; and at 2, 4, 6,12,18,24,30 months.&#xD;
&#xD;
        2. Disease activity was measured on the basis of the BVAS/WG and the physician's global&#xD;
           assessment.&#xD;
&#xD;
        3. Damage related to disease or treatment was scored according to the Vasculitis Damage&#xD;
           Index (scores for this index range from 0 to 64, with higher scores in- dicating more&#xD;
           severe damage).&#xD;
&#xD;
        4. Health related quality of life was scored with the use of the Med- ical Outcomes Study&#xD;
           36-Item Short-Form Health Survey (SF-36).Scores on this scale range from 0 to 100, with&#xD;
           higher scores indicating better health.&#xD;
&#xD;
        5. Serial serum samples were tested for proteinase 3-ANCA and myeloperoxidase-ANCA by means&#xD;
           of a direct enzyme-linked immunosorbent assay (ELISA).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">November 2017</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>30 Months</target_duration>
  <primary_outcome>
    <measure>Completely Remission</measure>
    <time_frame>6 months</time_frame>
    <description>BVAS/WG of 0 and successful completion of the prednisone taper at 6 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease flare</measure>
    <time_frame>during the period of observation(30months)</time_frame>
    <description>Disease flare&#xD;
an increase in the BVAS/WG of 1 point or more.&#xD;
Patients were classified as having early treatment failure if at 1 month their BVAS/WG had not decreased by at least 1 point or a new manifestation of disease had emerged.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse events</measure>
    <time_frame>during the period of observation (30months)</time_frame>
    <description>deaths (from all causes)&#xD;
malignant conditions&#xD;
grade 2 or higher leukopenia or thrombocytopenia&#xD;
grade 3 or higher infections&#xD;
drug induced cystitis&#xD;
venous thromboembolic events&#xD;
stroke&#xD;
hospitalizations</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>ANCA-associated Vasculitis</condition>
  <condition>Granulomatosis With Polyangiitis</condition>
  <condition>Microscopic Polyangiitis</condition>
  <condition>EosinphilicGranulomatosis With Polyangiitis</condition>
  <arm_group>
    <arm_group_label>Adults who diagosed ANCA-vasculitis</arm_group_label>
    <description>Patients with Wegener's granulomatosis or microscopic polyangiitis were eligible to participate in the study if they had&#xD;
Positive serum assays for proteinase 3-ANCA or myeloperoxidase-ANCA&#xD;
manifestations of severe disease,11 and a Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) of 3 or more (scores range from 0 to 63, with higher scores indicating more active disease)</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum lymphocytes urine&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who newly diagnosed ANCA-vasculitis&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males and Females&#xD;
&#xD;
          -  Aged from 18-75 years with informed consent&#xD;
&#xD;
          -  Patients with ANCA-vasculitis&#xD;
&#xD;
               1. Wegener's granulomatosis, microscopic polyangiitis or CSS&#xD;
&#xD;
               2. positive serum assays for proteinase 3-ANCA or myeloperoxidase-ANCA&#xD;
&#xD;
               3. manifestations of activity disease, and Birmingham Vasculitis Activity Score for&#xD;
                  Wegener's Granulomatosis (BVAS/WG) of 3 or more (scores range from 0 to 63, with&#xD;
                  higher scores indicating more active disease)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Females planning to bear a child recently or with childbearing potential&#xD;
&#xD;
          -  Secondary vasculitis, cancer,infective disease or drug induced vasculitis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juhong Shi, M.D</last_name>
    <role>Study Chair</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Juhong Shi, M.D</last_name>
    <phone>+861069155028</phone>
    <email>juhong_shi@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ling Qin, M.D</last_name>
    <phone>+861069155028</phone>
    <email>qinlingpumch@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <study_first_submitted>April 27, 2014</study_first_submitted>
  <study_first_submitted_qc>April 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2014</study_first_posted>
  <last_update_submitted>April 27, 2014</last_update_submitted>
  <last_update_submitted_qc>April 27, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 29, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ANCA-associated vasculitis</keyword>
  <keyword>Granulomatosis with polyangiitis</keyword>
  <keyword>Microscopic polyangiitis</keyword>
  <keyword>Wegner's granulomatosis</keyword>
  <keyword>Eosinphilic granulomatosis with polyangiitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Granulomatosis with Polyangiitis</mesh_term>
    <mesh_term>Microscopic Polyangiitis</mesh_term>
    <mesh_term>Vasculitis</mesh_term>
    <mesh_term>Systemic Vasculitis</mesh_term>
    <mesh_term>Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

